Background {#Sec1}
==========

Genome-wide association studies (GWASs) have linked more than ten thousand of single nucleotide polymorphisms (SNPs) to human diseases and traits \[[@CR1]\]. Given that a great part of associated variants are located in known tissue-specific enhancers, a recent study by Tehranchi and colleagues \[[@CR2]\] found that these non-coding variants affect transcription factors (TFs) binding and gene expression. Although they found that CCCTC-binding factor (CTCF) is likely to play a pioneering role in translating natural genetic variation in chromosomal architecture \[[@CR2]\], we still strive to understand tumor-specific epigenetic features that render possible progression toward such disease. For instance, previous approaches have been adopted to explore disease risk association with regulatory DNA elements \[[@CR3]--[@CR6]\].

In prostate cancer (PC) the androgen receptor (AR) binds predominantly to gene-distal sites and has been used by multiple groups to functionally annotate genetic risk loci based on overlaps with risk single nucleotide polymorphisms (SNPs) as measured in genome-wide association studies (GWAS), which in some cases are also predicted to affect AR binding \[[@CR7], [@CR8]\].

Epigenetic marks such as acetylation on Histone 3 lysine 27 (H3K27ac) have been used as annotation of enhancers \[[@CR9]\]. Moreover, regions of extended H3K27ac bound by combinations of mediator complex subunit 1 (MED1) and bromodomain containing protein 4 (BRD4) have been defined as super-enhancers important to determine cell identity \[[@CR10]--[@CR12]\]. BRD4 has proven to be involved in several diseases thanks to the small molecule inhibitor JQ1 \[[@CR13]\]. In PC cells, BRD4 was recently shown to bind to the AR and affect its activity \[[@CR14]\] while components of the mediator complex such as MED1 and MED12 were recently found to be implicated in advanced PC \[[@CR15], [@CR16]\].

SNPs associated with common diseases have been found to lie within enhancers driving transcriptional output and have been identified using different methods \[[@CR9]\]. For PC, the most recent methods include genotyping matched to expression quantitative trait loci analysis and epigenetic marks such as H3K27Ac combined with chromatin accessibility \[[@CR17], [@CR18]\] or additional combination of binding information for key TFs such as AR and FOXA1 \[[@CR19]\]. Here we combined information on H3K27ac profile with binding site data for BRD4 and MED12 to improve the functional annotation of PC risk SNPs based on a previously described enrichment analysis \[[@CR18]\].

We show that this method is able to capture SNPs associated not only with PC but also in the context of Breast Cancer (BC) and Lung Cancer (LC) susceptibility. We find that BRD4 is the key discriminant of tissue-specific super-enhancers and binds disease specific PC and BC low *p-*value risk SNPs. Enrichment of disease-specific risk SNPs is higher when BRD4 binding profile information is incorporated with other epigenetic marks such as H3K27Ac and MED components, than for binding profiles of key TFs implicated in disease development and progression such as the AR or estrogen receptor (ER). Inhibitors for BRD4 are in clinical trials. However, little is known about the contribution of BRD4 to brain diseases. In order to evaluate if similar principles apply also for heritable mental disorders we extended our framework to epigenetic marks including BRD4 binding derived from Schwann cells and applied the enrichment analysis to GWAS studies of mental disorders from the Psychiatric Genetics Consortium (PGC) \[[@CR20], [@CR21]\].

Methods {#Sec2}
=======

Data source for enhancers' annotation {#Sec3}
-------------------------------------

AR binding information in both LNCaP and VCaP cells was retrieved from Massie et al., (2011) \[[@CR22]\]. Raw data were aligned with novoalign to human genome version hg19, and peaks were called with MACS using default parameters after filtering low quality reads (score below 20). Resulting peaks were then overlapped using Bedtools. MED1 binding information and H3K27Ac profile in LNCaP cells was retrieved from Wang et al., (2012) \[[@CR23]\] and re-analyzed as described above. To define the degree of overlap with super-enhancers, we also downloaded super-enhancers coordinates from dbSUPER database \[[@CR24]\]. BRD4 binding information and H3K27Ac profile in VCaP cells was retrieved from Asangani et al., (2014) \[[@CR14]\]. ER and BRD4 binding information were retrieved from Nagarajan et al., (2014) \[[@CR25]\]. H3K27Ac profile in MCF7 was retrieved from Theodorou et al., (2013) \[[@CR26]\]. BRD4 and MED1 binding information, and H3K27Ac profile for small cell lung cancer (SCLC) cell line H2171 and Schwann cells were retrieved from cistrome \[[@CR27]\]. All cell-specific datasets were equally analyzed to ensure comparability within a tissue type.

Enhancers were defined in LNCaP based on (1) extended H3K27Ac marked regions ranging from 3000 bp to 200 kb (Additional file [1](#MOESM1){ref-type="media"}); (2) an intersection of these H3K27Ac marked regions with MED12 binding sites (Additional file [2](#MOESM2){ref-type="media"}). In VCaP cells enhancers were defined (3) as an extended H3K27Ac marked regions ranging from 3000 bp to 200 kb (Additional file [3](#MOESM3){ref-type="media"}) (4) the intersection of H3K27Ac stretches longer than 2000 bp and BRD4 binding sites (in VCaP cultured in presence of androgens) (Additional file [4](#MOESM4){ref-type="media"}) or (5) as BRD4 sites alone (Additional file [5](#MOESM5){ref-type="media"}). (6) To achieve a consensus map of super-enhancers in PC (Additional file [6](#MOESM6){ref-type="media"}) we selected super-enhancers found in LNCaP cells that were found to have H3K27Ac and BRD4 binding also in VCaP cells.

Enhancers in MCF7 cells were identified following the criteria described in Hnisz et al., (2013) \[[@CR12]\]. First, H3K27Ac peaks closer than 100 bp were merged, then only stretches longer than 2000 bp were selected (Additional file [7](#MOESM7){ref-type="media"}). Different compendia of enhancers were then created based on the presence of BRD4 (Additional file [8](#MOESM8){ref-type="media"}) and ER binding (Additional file [9](#MOESM9){ref-type="media"}) or the combination of these features (Additional files [10](#MOESM10){ref-type="media"} and [11](#MOESM11){ref-type="media"}). The same type of algorithm was followed to identify enhancers in H2171 and Schwann cells 90-8TL (Additional files [12](#MOESM12){ref-type="media"}, [13](#MOESM13){ref-type="media"}, [14](#MOESM14){ref-type="media"}, [15](#MOESM15){ref-type="media"}, [16](#MOESM16){ref-type="media"}, [17](#MOESM17){ref-type="media"} and [18](#MOESM18){ref-type="media"}). DNase I hypersensitive sites (DHS) profiles for LNCaP cells were retrieved from He et al. (2012) \[[@CR28]\] and from ENCODE (Additional files [19](#MOESM19){ref-type="media"} and [20](#MOESM20){ref-type="media"}). A more stringent profile of these two based on overlap (Additional file [21](#MOESM21){ref-type="media"}) was also included.

Data source for summary statistics of genome-wide association studies {#Sec4}
---------------------------------------------------------------------

We obtained summary statistics from large meta-analyses of the traits of interest. In particular, the summary statistics for association with PC risk were obtained from the Illumina array Collaborative Oncological Gene-environment Study (iCOGS) consortium \[[@CR29]\] and comprised information on 25,074 cases and 24,272 controls genotyped on a customized array including 211,155 SNPs. Additionally, we used summary statistics on 525,821 SNPs for association with PC risk derived from a smaller UK-based cohort including 1854 cases and 1854 controls in collaboration with the PRACTICAL consortium \[[@CR30]\]. Genetic association with BC risk was obtained in collaboration with the BCAC consortium and was derived from a meta-analysis including 15,863 cases and 40,022 controls on \~2.5 million SNPs \[[@CR31]\]. We collected also summary statistics for 14,900 cases of lung cancer (LC) and 29,485 controls including 2,433,836 SNPs from the TRICL consortium \[[@CR32]\]. From the IGAP consortium we obtained summary data from 17,008 Alzheimer\'s disease cases and 37,154 controls genotyped on 518,871 SNPs \[[@CR33]\]. Finally from the PGC consortium we used summary statistics on association with schizophrenia on 36,989 cases and 113,075 controls including 2,540,803 SNPs \[[@CR21]\], and summary statistics on association with bipolar disorder on 11,974 cases and 51,792 controls on a total of 2,382,073 SNPs \[[@CR20]\].

SNPs enrichment method {#Sec5}
----------------------

Enrichment is defined by the presence of lower *p-*values than expected by chance. Quantile-quantile (Q-Q) plots are tools commonly used in genetics to visualize enrichment \[[@CR18]\]. Typically, the observed *p*-value quantiles on the *y-*axes are plotted against the theoretical *p*-value quantiles under the assumption of no association (i.e. following the quantiles of the uniform distribution) on the *x-*axes. In case of no association, a Q-Q plot follows a straight 0--1 line starting from the origin. In the presence of association, the enrichment (of low *p*-values) is described by the deflection of the Q-Q plot from this theoretical line of no association. We used stratified Q-Q plots to assess differential enrichment of SNPs mapping to specific categories of enhancers. Stratified Q-Q plots have been used previously to demonstrate enrichment of general location annotation categories such as 5'UTR SNPs \[[@CR18]\].

Quantifying SNPs enrichment within sets of enhancers {#Sec6}
----------------------------------------------------

To assess the significance of the association enrichment among the sets of SNPs within enhancers we used Fisher's hypergeometric test. More specifically, we tested for over-representation of genome-wide significant SNPs (i.e. association of --log10 *p*-value \> 7.3) within specific enhancers. We adjusted for multiple testing using a Bonferroni-correction accounting for the number of annotations tested.

Random pruning {#Sec7}
--------------

The statistical models underlying the SNP enrichment analyses carried out here generally assume independence of the data. Far from resembling independent samples, SNPs are linked by complex correlation patterns reflected in their linkage disequilibrium (LD) structure. In order to adhere more closely to the independence assumption, and to rule out bias due to confounding factors such as LD, and assess whether the intrinsic capacity of functional annotations to enrich specific SNP sets was due to such confounding factors, the SNPs were randomly pruned prior to the analyses by randomly selecting representatives from all 1Mbase LD blocks of SNPs with pairwise *r* ^2^ ≥ 0.2. Iterating the random pruning procedure 100 times and subsequently averaging the corresponding test statistics compensated the arbitrariness in the choice of representative SNPs. These analyses were performed and shown in Additional file [22](#MOESM22){ref-type="media"}: Figures S1, S3, and S6.

Results {#Sec8}
=======

To assess whether tissue or cell-specific enhancers could mark tissue-specific risk SNPs associated with development of PC, we analyzed datasets from two studies that profiled MED12 binding and H3K27Ac map in LNCaP cells \[[@CR23]\], and BRD4 and H3K27Ac in VCaP cells \[[@CR14]\]. MED12, is a subunit of the same chromatin looping mediator complex as MED1 \[[@CR34]\] therefore we used it for our PC study assuming that these two subunits would have similar binding profiles in the same cells.

Enhancers were defined in LNCaP based on (1) extended H3K27Ac marked regions (Additional file [1](#MOESM1){ref-type="media"}); (2) an intersection of these H3K27Ac marked regions with MED12 binding sites (Additional file [2](#MOESM2){ref-type="media"}). In VCaP cells enhancers were defined as (3) extended H3K27Ac marked regions (Additional file [3](#MOESM3){ref-type="media"}) (4) the intersection of H3K27Ac stretches and BRD4 binding sites (Additional file [4](#MOESM4){ref-type="media"}) or (5) as BRD4 sites alone (Additional file [5](#MOESM5){ref-type="media"}). (6) To achieve a consensus map of enhancers in PC (Additional file [6](#MOESM6){ref-type="media"}) we intersected the enhancers found in both LNCaP and VCaP cells characterized by all three epigenetic features and responded to the definition of super-enhancers \[[@CR12]\] (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}).Table 1SNPs mapping to epigenetic marks used to define enhancers in prostate and breast cancerCell line/Tumor typeEpigenetic marksKey transcription factor^a^Number of SNPs within the intervals covered by the array:iCOGSPRACTICALBCACAllLNCaPH3K27Ac\-\-\--160530921348213503AR669127456645671LNCaPH3K27Ac + MED12\-\-\--685127154285442AR27954123102316VCaPH3K27Ac + BRD4\-\-\--58798342184239AR34250221482154VCaPBRD4\-\-\--859159579848066AR2360233233VCaPH3K27Ac\-\-\--389684403815038444PCH3K27Ac + MED12 + BRD4\-\-\--82130618619AR4946248249PC\-\-\--AR496140359505967MCF7H3K27Ac + BRD4\-\-\--8783210589396994858ER4296106074593746222MCF7H3K27Ac\-\-\--1927048028215997217382ER6710162066974370058MCF7BRD4\-\-\--28049526172641ER3466282282MCF7\-\-\--ER15837116381639^a^Binding information for key transcription factors such as androgen receptor (AR) or estrogen receptor (ER) where used alone or in combination with the epigenetic mark profiles in order to assess their capacity to refine enrichment of risk SNPs Fig. 1Definition of enhancers using chromatin marks and generic epigenetic readers. UCSC genome browser snapshot of the kallikreins locus showing enhancers identified in LNCaP based on MED12 binding information retrieved from Wang et al., (2012), and H3K27Ac profile retrieved from Hnisz et al., (2014) \[[@CR12]\]; Enhancers identified in VCaP based on BRD4 binding and H3K27Ac retrieved from Asangani et al., (2014) \[[@CR14]\]; and common enhancers in prostate cancer (PC) identified selecting enhancers in LNCaP which also had BRD4 and acetylation signature according to the compendium of enhancers in VCaP cells. In the locus shown here the long stretch of H3K27Ac includes also MED12 according to Wang et al., (2011) \[[@CR23]\] and BRD4 binding sites. At the bottom of the figure SNPs within these particular enhancers are indicated with the red line for SNPs found in the enhancers in LNCaP cells and PC common enhancers, and with the blue line for SNPs found in the enhancer in VCaP cells. Independent tracks for the androgen receptor (AR) binding sites in common in LNCaP and VCaP cells according to Massie et al., (2011) \[[@CR22]\] re-analyzed for this study are also shown

Enrichment of SNPs associated with prostate cancer in regions bound by MED and BRD4, marked by H3K27Ac in prostate cancer cells {#Sec9}
-------------------------------------------------------------------------------------------------------------------------------

First, we overlaid genome coordinates of enhancers in PC cell lines, as defined previously, with genomic coordinates of all SNPs in the PC iCOGS dataset \[[@CR29]\]. To visualize differential enrichment patterns of specific epigenetic markers with respect to their genetic association with PC risk we generated stratified Q-Q plots which is a method for visualizing the enrichment of statistical association relative to that expected under the global null hypothesis \[[@CR18]\]. Q-Q plots show that SNPs within regions with different genomic features (H3K27ac, BRD4, and MED12, or a combination of these) had different enrichment patterns compared to all SNPs (Fig. [2a](#Fig2){ref-type="fig"}). The SNPs contained in common PC enhancers, and therefore characterized by BRD4 and MED12 binding, and a long stretch of H3K27Ac had lower *p-*values than SNPs contained in enhancers identified in VCaP cells by mapping long stretches of H3K27Ac and BRD4 binding. SNPs associated with PC risk were more enriched within BRD4 binding sites alone than within H3K27Ac sites or H3K27Ac/MED12 overlapping sites in LNCaP. In addition, we focused on SNPs achieving genome wide significance and compared overrepresentation of these SNPs mapping to the above-described enhancers (Additional file [22](#MOESM22){ref-type="media"}: Table S1). 12% and 3% of the SNPs contained in PC enhancers achieved genome-wide significance in the iCOGS and in the PRACTICAL GWAS respectively. SNPs that achieved significance in iCOGs are listed in Additional file [22](#MOESM22){ref-type="media"}: Table S2. These results highlight that combining generic epigenetic marks such as H3K27Ac with generic epigenetic readers such as BRD4 and with MED binding increases the capacity of capturing SNPs associated with PC.Fig. 2Enrichment of SNPs lying within enhancers. Q-Q plots visualizing the *p*-value enrichment of sets of SNPs mapping within genomic intervals identified as regions of putative enhancers or key transcription factor binding sites. The *p*-values describe the association of a specific SNP with prostate (iCOGs in panel **a** & **b**; PRACTICAL in panel **c**) and breast cancer (BCAC in panel **d** & **e**). The genomic intervals represent regions bound by MED12, BRD4 with a H3K27Ac modification in prostate cancer cell lines (LNCaP and VCaP), or in overlapping regions profiled for a combination of the features in the prostate cancer (PC) cell-lines as indicated (**a**, **c**, **d**), intersected with AR binding sites (**b**), or regions found in MCF7 (**e**), as indicated in the legends. (**f**) Q-Q plots visualizing the *p*-value enrichment of schizophrenia associated SNPs (PGC) lying within enhancers identified in Schwann cells

Importantly, to rule out possible confounding factors, we first randomly pruned the SNPs, selecting one representative SNP per LD block. The random pruning did not change the enrichments patterns caused by the functional annotations (Additional file [22](#MOESM22){ref-type="media"}: Figure S1). Secondly, in order to rule out that the enrichment merely results from the non-independence of the SNPs in the enhancer regions or other confounding features of these, we compared the observed enrichment to the one attained on a set of SNPs numerically matching those in the enhancer regions on minor allele frequencies and mutual LD *r* ^2^ (Additional file [22](#MOESM22){ref-type="media"}: Figure S2). The numerically matched SNP set was also used as control set to assess the enrichment significance (Additional file [22](#MOESM22){ref-type="media"}: Table S1, S3, S4) by means of Fisher's hypergeometric test (see [Methods](#Sec2){ref-type="sec"}).

Enrichment of prostate cancer associated SNPs within androgen receptor binding information. {#Sec10}
-------------------------------------------------------------------------------------------

We also compared the genomic coordinates of the SNPs to the coordinates for AR binding sites (ARBSs). Despite the use in the literature of ARBSs for functional annotation of GWAS significant PC SNPs, intersecting enhancer information with AR binding data did not lead to any further enrichment of SNPs associated with PC compared with enhancer information alone (Fig. [2b](#Fig2){ref-type="fig"} and Additional file [22](#MOESM22){ref-type="media"}: Table S3). In particular, although intersecting AR binding information induced a slight left-shift of the Q-Q plot for enhancers marked by H3K27Ac, MED12, and BRD4 binding, and for enhancers marked by H3K27Ac and BRD4, the enrichment was caused by the same SNPs responsible for the enrichment without AR binding information (see Additional file [22](#MOESM22){ref-type="media"}: Table S1 and S3). Furthermore, enhancer information outperformed ARBSs profile alone, or in combination with H3K27Ac profile, in enriching for genome-wide significant *p-*valued SNPs in PC (Additional file [22](#MOESM22){ref-type="media"}: Table S3), and overlapping AR with BRD4 binding sites did not alter the superior capability of BRD4 (as in Fig. [2a](#Fig2){ref-type="fig"}) to enrich for disease associated SNPs. Interestingly, although DHSs have been used to predict locations of common disease-associated variation \[[@CR3]\], DHSs profiles enriched less than ARBSs alone (Additional file [22](#MOESM22){ref-type="media"}: Figure S3).

Validation of the enrichment method on an independent GWAS for prostate cancer. {#Sec11}
-------------------------------------------------------------------------------

Finally, we validated our results on the independent PC GWAS obtained from the PRACTICAL consortium measured on a smaller UK-based cohort \[[@CR30]\] (Fig. [2c](#Fig2){ref-type="fig"}). Again, we observed the strongest SNP enrichment in PC super-enhancers marked by H3K27Ac, MED12, and BRD4 binding.

BRD4 binding sites derived from prostate cancer cells do not enrich for SNPs associated with breast cancer {#Sec12}
----------------------------------------------------------------------------------------------------------

To test the specificity of BRD4, MED12 and H3K27Ac profiles in PC cells in identifying tissue-specific SNPs, we performed a similar enrichment analysis for genetic association with BC risk measured on the genotype array content from the BCAC \[[@CR31]\] (Fig. [2d](#Fig2){ref-type="fig"}). Enhancers defined on the basis of BRD4 binding profile in PC cells failed to enrich specifically for BC associated SNPs. Whilst H3K27ac and MED12 together achieved some enrichment of BC SNPs, the addition of BRD4 depleted this enrichment entirely. Importantly, once again, randomly pruning the SNPs did not alter the results of the enrichment analysis (Additional file [22](#MOESM22){ref-type="media"}: Figure S4). These results are in stark contrast to the analysis on PC datasets in which inclusion of BRD4 enhanced enrichment of low *p-*valued SNPs associated with PC, and suggests a hierarchical determination of tissue-specificity, based on the subsequential deposition of these epigenetic marks. Taken together, this indicates that BRD4 substantially contributes to prostate-specific SNP enrichment within super-enhancers.

Of note, the genomic distribution of the BCAC SNP array mirrored the genomic distribution of the SNP arrays used for iCOGS with the majority of SNPs located within intronic (48% and 57%, respectively) and intergenic (48% and 34%, respectively) regions of the genome (Additional file [22](#MOESM22){ref-type="media"}: Figure S5) thus meaning that whilst the number of SNPs differed between the PC and BC studies, there was no genomic distribution bias for imputed SNPs. The SNPs included within the enhancers defined in this study reflected similar distributions, with the only exception of SNPs lists derived from LNCaP cells that were slightly biased toward intergenic regions. Around 69% to 77% of the SNPs were located within intergenic regions (data not shown).

Enrichment of SNPs associated with breast cancer in regions bound by BRD4, marked by H3K27Ac in breast cancer cells {#Sec13}
-------------------------------------------------------------------------------------------------------------------

Next, we sought to identify whether using BC-specific epigenetic profiles for the same markers derived from the BC cell line MCF7, we would be able to repeat the same performance as in the PC enrichment analysis. Therefore we retrieved genome-wide profiles of H3K27Ac, ER, and BRD4 binding in MCF7 \[[@CR25]\], compiled a similar list of enhancers (Table [1](#Tab1){ref-type="table"} and Additional file [22](#MOESM22){ref-type="media"}: Figure S6), and performed an enrichment analysis of association with BC risk on the BCAC GWAS (Fig. [2e](#Fig2){ref-type="fig"} and Additional file [22](#MOESM22){ref-type="media"}: Table S4). Information on MED binding is not available for BC cell lines. However, BRD4 binding information alone caused the strongest enrichment of SNPs associated with BC (Additional file [22](#MOESM22){ref-type="media"}: Table S5). These data confirm that BRD4 alone is an important enhancer and super-enhancer discriminant, which binds disease-specific susceptibility loci in a tissue specific fashion. Randomly pruning the SNPs involved, proved not to alter the capacity of BRD4 of capturing disease-specific associated SNPs (Additional file [22](#MOESM22){ref-type="media"}: Figure S7). Interestingly, pruning the SNPs revealed that ER capability to capture disease associated SNPs in combination with other epigenetic features was enhanced, possibly suggesting a different contribution of ER and AR in breast and PC pathogenesis, respectively.

As counterproof, we tested whether BC epigenetic profiles caused any enrichment in iCOGS PC associations, but no such enrichment was detected (Additional file [22](#MOESM22){ref-type="media"}: Figure S8). These results are consistent with BRD4 binding being cell and tissue-specific \[[@CR35]\]. Moreover, these results pinpoint the tissue-specificity of risk loci and hint that BRD4 activity may be influenced by genetic variations as it is for TFs \[[@CR2]\].

Enrichment of risk SNPs associated with lung cancer and psychiatric traits using H3K27Ac profiles, BRD4, and MED binding sites derived from relevant cell lines {#Sec14}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

To understand whether the properties of BRD4 binding to clinically relevant genetic risk loci is confined to PC and BC only, or such selectivity can also be observed to other diseases and traits, we retrieved binding information for BRD4, MED1 and H3K27Ac profiles available for the lynphoblastoid cell line H2171 derived from a metastatic site in a LC patient \[[@CR10]\] and from the malignant peripheral nerve sheath tumor Schwann cells 90-8TL \[[@CR36]\] (Additional files [12](#MOESM12){ref-type="media"}, [13](#MOESM13){ref-type="media"}, [14](#MOESM14){ref-type="media"}, [15](#MOESM15){ref-type="media"}, [16](#MOESM16){ref-type="media"}, [17](#MOESM17){ref-type="media"} and [18](#MOESM18){ref-type="media"}). To retrieve associations of these epigenetic features with other phenotypes we collected summary statistics for LC \[[@CR32]\], Alzheimer's disease \[[@CR33]\], schizophrenia \[[@CR21]\], and bipolar disorder \[[@CR20]\].

BRD4 binding information alone caused the strongest enrichment of associations with LC, although combined information for BRD4 and MED1 binding, also combined with H3K27Ac profile failed to improve the enrichment of low *p*-value SNPs (Additional file [22](#MOESM22){ref-type="media"}: Figure S9a). We speculate that the LC cell line H2171 might not reflect characteristics of the tissue of origin, as well as the PC and BC cell lines. However, upon assessing the enrichment using epigenetic features related to PC cells for the same LC GWAS (Additional file [22](#MOESM22){ref-type="media"}: Figure S9b), as expected, we detected none, confirming that BRD4 binding information in H2171 retains some tissue-specificity and capacity to enrich for LC tissue-specific risk SNPs.

Next, we applied our enrichment method to perform an inverse analysis in which we sought to understand whether any association could be found between epigenetic features related to Schwann cells (the only brain cells for which H3K27Ac profile and BRD4 binding information were publicly available) and three diseases affecting the brain. No enrichment for SNPs associated with Alzheimer disease and bipolar disorder was detected (Additional file [22](#MOESM22){ref-type="media"}: Figure S10a&b). However, low *p*-valued SNPs associated with schizophrenia were highly enriched within BRD4 binding sites (Fig. [2f](#Fig2){ref-type="fig"}). Interestingly H3K27Ac profiles also enriched substantially for clinically relevant SNPs associated with schizophrenia. These data suggest that BRD4 activity in Schwann cells could potentially be involved in the etiology of schizophrenia \[[@CR37]\], and grant further investigation on the molecular mechanism underlying these findings.

Discussion {#Sec15}
==========

With the discovery of significant numbers of cancer genetic risk loci through GWAS there is now a major focus on the functional annotation of these loci to prioritize them for further biological study. So far this annotation has been undertaken Post-GWAS and has often employed classifiers of open chromatin, for example DHS, as a primary annotation followed by genome-wide binding maps for tissue-specific transcription factors such as the AR for PC or the ER for BC, while combining this information with H3K27Ac and open chromatin in a tissue-specific manner \[[@CR38]\]. In this study we ask whether it is possible to use binding sites data and chromatin marks upfront to enrich for genetic risk factors in a cancer type-specific manner. We show that an enhancer signature comprising a number of factors but dominated by BRD4 allows for the enrichment of PC-specific and BC-specific genetic risk loci (Fig. [3a](#Fig3){ref-type="fig"} and [b](#Fig3){ref-type="fig"} ). Interestingly, these chromatin features have been previously reported to be characteristic of super-enhancer-like profiles \[[@CR10]--[@CR12], [@CR35]\]. We found a strong degree of tissue-specificity, that is when profiles are derived from cell-lines associated with specific cancer types such as the cancer of the breast and prostate, they become far more effective at enriching for cancer-type specific risk loci than other widely used cancer type-specific TFs such as the AR, ER or DHSs alone. We also applied this enrichment strategy to infer that BRD4 binding information may allow in future for the upfront nomination of genomic-regions for high-coverage sequencing in risk studies for schizophrenia (Fig. [3c](#Fig3){ref-type="fig"}). Functional determination of the impact of risk SNPs have been the priority of several consortia aiming to uncover the effects on epigenetics mediated by clinically relevant risk variants located in non-exonic regions \[[@CR39]\]. Our study implies a conserved and important relationship between enhancers and cancer-associated risk loci, which is being pinpointed also by recent work linking the effect of genetic variation to TFs binding \[[@CR2]\]. Our approach is the first one that implies an effect of such genetic variations on the activity of generic epigenetic readers. This is also the first time that such epigenetic readers have been evaluated as enrichment factors for SNPs without prior filtering based on published *p-*values for risk association.Fig. 3Circular plots of GWAS significant SNPs overlapping with putative super-enhancers. The outmost circles depict chromosome-wise histograms showing p-values of SNP loci (LD r\^2 \< 0.2 within 1Mbase) representatives for SNPs in iCOGS (**a**), for SNPs in BCAC (**b**), and for SNPs associated with schizophrenia according to PGC (**c**). GWAS-significant SNPs are labeled and the nearby genes are also indicated. The inmost circle represents super-enhancers regions identified in prostate cancer cells (SE_PC_BRD4_MED12_H3K27Ac) (**a**), breast cancer cells (SE_MCF7_BRD4) (**b**), and in Schwann cells (SE_Schwann_BRD4) (**c**) that were most enriched of low p-value SNPs

We highlight the possibility that SNPs lying within super-enhancers marked by BRD4 are more likely to be associated with an increased susceptibility to BC, PC, and schizophrenia. The expression of the genes regulated by enhancers identified in these diseases could be altered by the presence of specific SNPs lying therein (Additional file [22](#MOESM22){ref-type="media"}: Figure S11). This is a concept that has recently been postulated for cancer mutations occurring in a chromatin-specific context \[[@CR40]\].

Conclusions {#Sec16}
===========

In conclusion we have discovered that BRD4-bound super-enhancers provide a powerful tool for enriching and prioritizing PC and BC genetic risk loci (Fig. [4](#Fig4){ref-type="fig"}), and have shown that key TFs such as AR or ER, despite being pivotal tissue-specific TFs, do not contribute to tissue-specific genetic risk enrichment more than epigenetic factors. We propose to refine disease specific risk loci enrichment with the identification of potential binding of BRD4 combined with key MED components and acetylation profiles. Our study will promote the use of BRD4 for SNP annotation as the genetic landscape for different diseases goes on expanding.Fig. 4Tissue-specific super-enhancers usage and identification of clinically relevant genetic variations associated with diseases and traits. The method for prioritization of clinically relevant SNPs is based on the identification of risk SNPs with GWAS significance that are associated with BRD4 binding to chromatin, within tissue-specific super-enhancers rather transcription factors binding
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